Jointly presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing

Supported by educational grants from Bristol-Myers Squibb, Gilead Sciences, Inc., and Merck & Co., Inc.

dkb header

Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study

a podcast by Raymond T. Chung, MD and David L. Wyles, MD dkb icon

You are using an outdated browser. Please upgrade your browser or activate Google Chrome Frame to improve your experience.